Format

Send to

Choose Destination
J Fr Ophtalmol. 2018 Nov;41(9):862-867. doi: 10.1016/j.jfo.2018.06.002. Epub 2018 Oct 22.

[Update from France Macula Federation: Treatment of Wet AMD].

[Article in French]

Author information

1
Centre hospitalier national d'ophtalmologie des XV-XX, 28, rue de Charenton, 75012 Paris, France; Centre ophtalmologique Vincennes, 17, bis rue des Meuniers, 94300 Vincennes, France.
2
Centre pôle vision, clinique du Val d'Ouest, Croix rousse, 39, chemin de la Vernique, 69130 Écully, France.
3
Centre pôle vision, clinique du Val d'Ouest, Croix rousse, 39, chemin de la Vernique, 69130 Écully, France; Hôpital de la Croix-Rousse, 103 grande rue de la Croix-Rousse, 69004 Lyon, France.
4
Centre ophtalmologique de la maison rouge, 6, rue de l'Église, 67000 Strasbourg, France.
5
Service d'ophtalmologie et université Paris Est, 61, avenue du Général de Gaulle, 94000 Créteil, France.
6
Service d'ophtalmologie et université Paris Est, 61, avenue du Général de Gaulle, 94000 Créteil, France; Centre ophthalmologique d'imagerie et de laser, 11, rue Antoine Bourdelle, 75015 Paris, France. Electronic address: sycsyc75@gmail.com.

Abstract

PURPOSE:

To update the recommendations of the France Macula Federation for treatment of wet age-related macular degeneration (AMD).

METHODS:

Analysis of literature and expert opinion.

RESULTS:

The FFM recommends initiating anti-VEGF therapy as soon as possible after diagnosis of exudative AMD. There has been no major change in the last several years concerning the procedure of intravitreal injection itself. However, the litigious points are discussed: simultaneous bilateral injection; antibiotic therapy; medico-legal aspects. All anti-VEGF strategies possess advantages and limitations. The strategy should be left to the ophthalmologists' preference. However, the chosen strategy should be explained to patients and strictly followed.

CONCLUSION:

The treatment of wet-AMD is more precisely codified than before. However, various strategies still coexist.

KEYWORDS:

Aflibercept; Anti-VEGF; Bevacizumab; DMLA exsudative; Ranibizumab; Wet AMD

PMID:
30361178
DOI:
10.1016/j.jfo.2018.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center